Corporate / CVC · 3 deals
Venture arm of global life sciences firm SPRIM
Singapore, OS
Every published round SPRIM Global Investments took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| Vaxxas | Venture debt | Aug 2025 | $40m | Participant | Startup Daily (29 Aug 2025), SmartCompany, Startup Daily (26 Aug 2025), Business News Australia | |
| Vaxxas | Series D+ | Aug 2025 | $49m | Lead | Startup Daily (23 Dec 2025), SmartCompany (23 Dec 2025), Startup Daily (14 Oct 2025), Cut Through Venture, Startup Daily (29 Aug 2025), SmartCompany (29 Aug 2025), Startup Daily (26 Aug 2025), Business News Australia | |
| Prota Therapeutics | Series A | Jan 2024 | $31.6m | Lead | SmartCompany (26 Apr 2024), SmartCompany (10 Apr 2024), Forbes Australia, Business News Australia, SmartCompany (19 Jan 2024), Startup Daily |
Companies SPRIM Global Investments has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| Vaxxas | Biotech/MedTech company | Aug 2025, Venture debt | 2 | 1 |
| Prota Therapeutics | Jan 2024, Series A | 1 | 1 |
Fund closes reported for SPRIM Global Investments, as distinct from the investments it has made.
Companies SPRIM Global Investments has backed that another company then bought. An exit for the holding, not a deal SPRIM Global Investments did.
| Name | Role | Sources |
|---|---|---|
| Michael Shleifer | Co-founder and Managing Partner | Startup Daily, Business News Australia, sprim.com |
Stories naming SPRIM Global Investments. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Weekly roundup detailing five Australian raises: Vaxxas' Series D plus debt facility amid executive changes, Skutopia's growth round, Send Payments' backing and CEO change, Apate.ai's seed, and Coursebox's seed.
Also Startup Daily·SmartCompany·Australian FinTech·Dealroom·Startup Daily
Australian biotech Vaxxas secured a Series D plus a debt facility while overhauling leadership: a new chair, founding CEO shifting to an advisory role, and CFO made redundant amid job cuts.
Also Business News Australia·SmartCompany·Cut Through Venture·Startup Daily·Startup Daily·SmartCompany·Startup Daily
Vaxxas announced a roughly A$90m financing — Series D equity led by SPRIM Global Investments plus debt — to advance its needle-free vaccine patch, alongside leadership changes including a new chair.
Roundup of January 2024 funding: Futurerent, Prota Therapeutics, National Renewable Network and Getmee together secured $94.5 million across debt, equity and a government grant, with investor details for each deal.
Prota Therapeutics, a Melbourne biotech, has secured $32 million in equity and debt ahead of a Phase 3 trial of its peanut allergy therapy, with Singapore's SPRIM Global Investments leading the round.
Also SmartCompany·SmartCompany·SmartCompany·Business News Australia·Forbes Australia